Q2 2014 · 10-Q
Revenue$6.84M$6.84M −29.2% vs Q2 2013−53.2% vs Q1 2014
Net income—
EPS Diluted-$0.44-$0.44 N/M vs Q2 2013N/M vs Q1 2014
Operating Income-$55,119,000N/M
Operating Cash Flowderived-$36,210,000N/M
Free Cash Flowderived-$36,939,000N/M
Margins · derived
Operating margin-805.8%−186.2 pt vs Q2 2013
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2014 | Q2 2013 | Q2 2012 | Q2 2011 |
|---|---|---|---|---|
| Revenue | $6.84M | $9.66M | $14.60M | $11.26M |
| Net Income | — | — | — | -$18.84M |
| EPS Diluted | -$0.44 | -$0.57 | -$0.38 | -$0.19 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ironwood Pharmaceuticals Inc · CIK 1446847 · Engraved from SEC EDGAR